Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 12,100 shares at $6.67 ($81K) on 2014-10-15, disclosed to the SEC on 2014-10-17.
Scheduled sale ($81k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.67 | 4,300 | $29K | 35.2% |
| 2 | $6.76 | 4,800 | $32K | 39.8% |
| 3 | $6.79 | 3,000 | $20K | 25.0% |
| Total | $6.74 avg | 12,100 | $81K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |
| RGLS | SELL | 2014-10-03 | $69K | — | Filing → |